-
1
-
-
84883555597
-
-
Wang F. Zhang Y. eds. Beijing: People's Medical Publishing House
-
Wang F, Zhang Y, eds. Practical antimicrobial therapeutics. Beijing: People's Medical Publishing House, 2004.
-
(2004)
Practical Antimicrobial Therapeutics
-
-
-
2
-
-
70350776530
-
Comparative analysis of length of stay, total costs, and treatment success between intravenous moxifloxacin 400 mg and levofloxacin 750 mg among hospitalized patients with community-acquired pneumonia
-
Friedman H, Song X, Crespi S, Navaratnam P,. Comparative analysis of length of stay, total costs, and treatment success between intravenous moxifloxacin 400 mg and levofloxacin 750 mg among hospitalized patients with community-acquired pneumonia. Value Health, 2009; 12: 1135-1143.
-
(2009)
Value Health
, vol.12
, pp. 1135-1143
-
-
Friedman, H.1
Song, X.2
Crespi, S.3
Navaratnam, P.4
-
3
-
-
67649354667
-
Medical resource utilization among community-acquired pneumonia patients initially treated with levofloxacin 750 mg daily versus ceftriaxone 1000 mg plus azithromycin 500 mg daily: A US-based study
-
Frei CR, Jaso TC, Mortensen EM, et al,. Medical resource utilization among community-acquired pneumonia patients initially treated with levofloxacin 750 mg daily versus ceftriaxone 1000 mg plus azithromycin 500 mg daily: a US-based study. Curr Med Res Opin, 2009; 25: 859-868.
-
(2009)
Curr Med Res Opin
, vol.25
, pp. 859-868
-
-
Frei, C.R.1
Jaso, T.C.2
Mortensen, E.M.3
-
4
-
-
41149152915
-
A comparison of levofloxacin and moxifloxacin use in hospitalized community-acquired pneumonia (CAP) patients in the US: Focus on length of stay
-
Schein J, Janagap-Benson C, Grant R, Sikirica V, Doshi D, Olson W,. A comparison of levofloxacin and moxifloxacin use in hospitalized community-acquired pneumonia (CAP) patients in the US: focus on length of stay. Curr Med Res Opin, 2008; 24: 895-906.
-
(2008)
Curr Med Res Opin
, vol.24
, pp. 895-906
-
-
Schein, J.1
Janagap-Benson, C.2
Grant, R.3
Sikirica, V.4
Doshi, D.5
Olson, W.6
-
6
-
-
0034956120
-
Safety and pharmacokinetics of multiple 750-milligram doses of intravenous levofloxacin in healthy volunteers
-
Chow AT, Fowler C, Williams RR, Morgan N, Kaminski S, Natarajan J,. Safety and pharmacokinetics of multiple 750-milligram doses of intravenous levofloxacin in healthy volunteers. Antimicrob Agents Chemother, 2001; 45: 2122-2125.
-
(2001)
Antimicrob Agents Chemother
, vol.45
, pp. 2122-2125
-
-
Chow, A.T.1
Fowler, C.2
Williams, R.R.3
Morgan, N.4
Kaminski, S.5
Natarajan, J.6
-
7
-
-
77952271412
-
Levofloxacin in the treatment of community-acquired pneumonia
-
Noreddin AM, Elkhatib WF,. Levofloxacin in the treatment of community-acquired pneumonia. Expert Rev Anti Infect Ther, 2010; 8: 505-514.
-
(2010)
Expert Rev Anti Infect Ther
, vol.8
, pp. 505-514
-
-
Noreddin, A.M.1
Elkhatib, W.F.2
-
8
-
-
40349113718
-
Levofloxacin: A review of its use as a high-dose, short-course treatment for bacterial infection
-
Anderson VR, Perry CM,. Levofloxacin: a review of its use as a high-dose, short-course treatment for bacterial infection. Drugs, 2008; 68: 535-565.
-
(2008)
Drugs
, vol.68
, pp. 535-565
-
-
Anderson, V.R.1
Perry, C.M.2
-
9
-
-
5444275363
-
Clinical implications of 750 mg, 5-day levofloxacin for the treatment of community-acquired pneumonia
-
File TM Jr, Milkovich G, Tennenberg AM, Xiang JX, Khashab MM, Zadeikis N,. Clinical implications of 750 mg, 5-day levofloxacin for the treatment of community-acquired pneumonia. Curr Med Res Opin, 2004; 20: 1473-1481.
-
(2004)
Curr Med Res Opin
, vol.20
, pp. 1473-1481
-
-
File, Jr.T.M.1
Milkovich, G.2
Tennenberg, A.M.3
Xiang, J.X.4
Khashab, M.M.5
Zadeikis, N.6
-
10
-
-
70350508580
-
Clinical evaluation of oral levofloxacin 500 mg once-daily dosage for treatment of lower respiratory tract infections and urinary tract infections: A prospective multicenter study in China
-
Zhang YY, Huang HH, Ren ZY, et al,. Clinical evaluation of oral levofloxacin 500 mg once-daily dosage for treatment of lower respiratory tract infections and urinary tract infections: a prospective multicenter study in China. J Infect Chemother, 2009; 15: 301-311.
-
(2009)
J Infect Chemother
, vol.15
, pp. 301-311
-
-
Zhang, Y.Y.1
Huang, H.H.2
Ren, Z.Y.3
-
11
-
-
70350503434
-
Population pharmacokinetics of oral levofloxacin 500 mg once-daily dosage in community-acquired lower respiratory tract infections: Results of a prospective multicenter study in China
-
Zhang J, Xu JF, Liu YB, et al,. Population pharmacokinetics of oral levofloxacin 500 mg once-daily dosage in community-acquired lower respiratory tract infections: results of a prospective multicenter study in China. J Infect Chemother, 2009; 15: 293-300.
-
(2009)
J Infect Chemother
, vol.15
, pp. 293-300
-
-
Zhang, J.1
Xu, J.F.2
Liu, Y.B.3
-
12
-
-
0037229596
-
Worldwide antimicrobial susceptibility patterns and pharmacodynamic comparisons of gatifloxacin and levofloxacin against Streptococcus pneumoniae: Report from the Antimicrobial Resistance Rate Epidemiology Study Team
-
Jones RN, Rubino CM, Bhavnani SM, Ambrose PG,. Worldwide antimicrobial susceptibility patterns and pharmacodynamic comparisons of gatifloxacin and levofloxacin against Streptococcus pneumoniae: report from the Antimicrobial Resistance Rate Epidemiology Study Team. Antimicrob Agents Chemother, 2003; 47: 292-296.
-
(2003)
Antimicrob Agents Chemother
, vol.47
, pp. 292-296
-
-
Jones, R.N.1
Rubino, C.M.2
Bhavnani, S.M.3
Ambrose, P.G.4
-
14
-
-
79959220301
-
Pharmacokinetics of intravenous levofloxacin administered at 750 milligrams in obese adults
-
Cook AM, Martin C, Adams VR, Morehead RS,. Pharmacokinetics of intravenous levofloxacin administered at 750 milligrams in obese adults. Antimicrob Agents Chemother, 2011; 55: 3240-3243.
-
(2011)
Antimicrob Agents Chemother
, vol.55
, pp. 3240-3243
-
-
Cook, A.M.1
Martin, C.2
Adams, V.R.3
Morehead, R.S.4
-
15
-
-
73849139599
-
Pharmacometrics-based dose selection of levofloxacin as a treatment for postexposure inhalational anthrax in children
-
Li F, Nandy P, Chien S, Noel GJ, Tornoe CW,. Pharmacometrics-based dose selection of levofloxacin as a treatment for postexposure inhalational anthrax in children. Antimicrob Agents Chemother, 2010; 54: 375-379.
-
(2010)
Antimicrob Agents Chemother
, vol.54
, pp. 375-379
-
-
Li, F.1
Nandy, P.2
Chien, S.3
Noel, G.J.4
Tornoe, C.W.5
-
16
-
-
33744486890
-
Levofloxacin pharmacokinetics and pharmacodynamics in patients with severe burn injury
-
Kiser TH, Hoody DW, Obritsch MD, Wegzyn CO, Bauling PC, Fish DN,. Levofloxacin pharmacokinetics and pharmacodynamics in patients with severe burn injury. Antimicrob Agents Chemother, 2006; 50: 1937-1945.
-
(2006)
Antimicrob Agents Chemother
, vol.50
, pp. 1937-1945
-
-
Kiser, T.H.1
Hoody, D.W.2
Obritsch, M.D.3
Wegzyn, C.O.4
Bauling, P.C.5
Fish, D.N.6
-
17
-
-
0041767551
-
Steady-state plasma and bronchopulmonary concentrations of intravenous levofloxacin and azithromycin in healthy adults
-
Rodvold KA, Danziger LH, Gotfried MH,. Steady-state plasma and bronchopulmonary concentrations of intravenous levofloxacin and azithromycin in healthy adults. Antimicrob Agents Chemother, 2003; 47: 2450-2457.
-
(2003)
Antimicrob Agents Chemother
, vol.47
, pp. 2450-2457
-
-
Rodvold, K.A.1
Danziger, L.H.2
Gotfried, M.H.3
-
18
-
-
34548115791
-
Pharmacodynamics of moxifloxacin and levofloxacin against Streptococcus pneumoniae, Staphylococcus aureus, Klebsiella pneumoniae and Escherichia coli: Simulation of human plasma concentrations after intravenous dosage in an in vitro kinetic model
-
Odenholt I, Cars O,. Pharmacodynamics of moxifloxacin and levofloxacin against Streptococcus pneumoniae, Staphylococcus aureus, Klebsiella pneumoniae and Escherichia coli: simulation of human plasma concentrations after intravenous dosage in an in vitro kinetic model. J Antimicrob Chemother, 2006; 58: 960-965.
-
(2006)
J Antimicrob Chemother
, vol.58
, pp. 960-965
-
-
Odenholt, I.1
Cars, O.2
-
19
-
-
24144484187
-
Pharmacodynamic analysis of ceftriaxone, gatifloxacin, and levofloxacin against Streptococcus pneumoniae with the use of Monte Carlo simulation
-
Frei CR, Burgess DS,. Pharmacodynamic analysis of ceftriaxone, gatifloxacin, and levofloxacin against Streptococcus pneumoniae with the use of Monte Carlo simulation. Pharmacotherapy, 2005; 25: 1161-1167.
-
(2005)
Pharmacotherapy
, vol.25
, pp. 1161-1167
-
-
Frei, C.R.1
Burgess, D.S.2
-
20
-
-
9644303233
-
Pharmacokinetics and pharmacodynamics of intravenous levofloxacin at 750 milligrams and various doses of metronidazole in healthy adult subjects
-
Sprandel KA, Schriever CA, Pendland SL, et al,. Pharmacokinetics and pharmacodynamics of intravenous levofloxacin at 750 milligrams and various doses of metronidazole in healthy adult subjects. Antimicrob Agents Chemother, 2004; 48: 4597-4605.
-
(2004)
Antimicrob Agents Chemother
, vol.48
, pp. 4597-4605
-
-
Sprandel, K.A.1
Schriever, C.A.2
Pendland, S.L.3
-
21
-
-
0033755095
-
Comparative in vitro activity and pharmacodynamics of five fluoroquinolones against clinical isolates of Streptococcus pneumoniae
-
Kays MB, Conklin M,. Comparative in vitro activity and pharmacodynamics of five fluoroquinolones against clinical isolates of Streptococcus pneumoniae. Pharmacotherapy, 2000; 20: 1310-1317.
-
(2000)
Pharmacotherapy
, vol.20
, pp. 1310-1317
-
-
Kays, M.B.1
Conklin, M.2
-
22
-
-
23044505177
-
Study of pharmacokinetics/pharmacodynamics of levofloxacin
-
Zhang J, Yu JC, Shi YG, Zhou L, Ye XY, Zhu DM, Zhang YY., Study of pharmacokinetics/pharmacodynamics of levofloxacin. Zhonghua Yi Xue Za Zhi, 2005; 85: 1926-1932.
-
(2005)
Zhonghua Yi Xue Za Zhi
, vol.85
, pp. 1926-1932
-
-
Zhang, J.1
Yu, J.C.2
Shi, Y.G.3
Zhou, L.4
Ye, X.Y.5
Zhu, D.M.6
Zhang, Y.Y.7
|